| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| See Tai Sandi | Chief Development Officer | C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK | /s/ Youjin Choi, Attorney-in-Fact | 2025-10-17 | 0002009350 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LXEO | Common Stock | Award | $0 | +10.9K | +18.5% | $0.00 | 69.8K | Oct 15, 2025 | Direct | |
| transaction | LXEO | Common Stock | Sale | -$34.3K | -3.84K | -5.51% | $8.94 | 65.9K | Oct 17, 2025 | Direct | F1, F2 |
| transaction | LXEO | Common Stock | Sale | -$421 | -44 | -0.07% | $9.56 | 65.9K | Oct 17, 2025 | Direct | F1, F3, F4 |
| Id | Content |
|---|---|
| F1 | Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs"). |
| F2 | This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F3 | This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F4 | Includes 49,138 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. |